Embody Weight Loss Results: What You Can Really Expect (and What the Ads Don't Say)

Embody weight loss results, in short: Embody's ads claim 18% loss in six months, but we couldn't independently verify its self-reported average. Its refund policy doesn't guarantee results. Consider its cash-pay compounded route only when approved medicine cannot meet your medical needs—not for trial-proven Embody results. A separate Mayo study averaged 10.9% with semaglutide at six months.¹²³⁴

Embody results at a glance

Already taking Embody and the scale isn't moving? Jump to what to check first.

Your own result depends on your treatment, health, and how you respond—not just a headline average. Below, we put the results claims we found next to published studies, with each study's time period and patient group clearly marked. Then we show a six-fill cost illustration, and what to check before your first payment and every renewal.

Bottom line: Embody lists lower cash prices than the brand-name examples below. Just don't buy it for the 18%. Its public pages don't give us enough information to verify that average, and its refund policy doesn't promise results.⁷¹²

Best for: Adults paying cash whose clinician identifies a medical need an FDA-approved drug cannot meet, and who accept compounded medicine, a vial and syringe, and no results-based refund. Compounded means a pharmacy prepares medicine to meet a patient's needs; it is not FDA-approved.³²

Not best for: People who want an FDA-approved product with its own trial evidence, want Embody to bill insurance or Medicare, or want a pill. If you're pregnant, planning a pregnancy, breastfeeding, under 18, or have had an eating disorder, talk with your own clinician first.⁹¹⁰⁵

The factor that matters most: A treatment and follow-up plan you can sustain with your clinician. In a Cleveland Clinic study of brand-name medicine, people who stayed on for a year lost 11.9% on average. People who stopped in the first three months lost 3.6%. These were observed groups—not proof that staying on would give everyone the same result.¹¹

Here's the honest trade. Embody's policy offers no results guarantee, and payments are generally final. Its medical-disqualification exception refunds unused value after charges for services already provided—not necessarily every dollar. If you want an FDA-approved medicine with trial evidence, your own prescriber or Ro can be a different route; we haven't verified a results guarantee from Ro either.²¹²

At an unchanged $79 product-page price, six supplies of compounded semaglutide would total $474. The Wegovy pen example below totals $2,578 for six fills plus six Ro membership payments. Those are conditional cost illustrations, not six-calendar-month quotes or equivalent treatments. The lower price alone does not make a compounded prescription appropriate.⁷¹²¹³³

If that trade makes sense for you, start with the price for your plan and your state. Embody's public offer FAQ excludes Louisiana and requires age 19 or older in Nebraska. It also contains unclear dose units, so don't use its marketing page as treatment instructions. Ask how you'll receive a clear prescription and pharmacy walkthrough. You pay at checkout, and a licensed clinician decides afterward whether treatment is right for you.⁸

How much weight do people lose on Embody?

The Embody pages we checked do not identify a supporting study, patient count, or collection dates for the 18% figure. Its sale page attributes that average to patients' own weight reports during their first six months. That makes 18% an unverified marketing claim—not an established average for a new patient.¹

On September 24, 2026, we read Embody's homepage, its semaglutide and tirzepatide product pages, the sale page it runs for new patients, and the fine print on each. The table covers the claims on those pages. A separate Embody offer page also publishes different numbers, which we check in the timeline section.

Here, “No” means the checked public pages do not provide enough information to verify the result—not that we proved the claim false. Different patient counts may refer to different groups or dates; the page does not explain them.

The same pages carry this fine print:

• All claims "refer to self-reported data." Customers typed their weight on a form every 3–4 weeks.
• Some results shown are "not typical."
• People in ads "may be actors or models," and testimonial images "may use models."
• Some content "may be generated or enhanced using artificial intelligence."

Where the 18% comes from

Self-reported means patients typed their own weight into a form. Embody's public method does not tell us whether anyone independently checked those weights.¹

We also don't know how Embody handled people who stopped reporting. Leaving them out could change the average; including them would require a stated method for the missing weights. The page doesn't explain which it did.¹

Think of a class average that only counts the students who stayed for the final exam. Those grades may be real. They just aren't everyone's. That's the risk we're checking for—not proof that Embody used that method.

This matters because a lot of people stop. In a Cleveland Clinic study of 7,881 adults on brand-name semaglutide or tirzepatide, about half stopped within a year. In a published study of an online weight program, only 655 of 4,500 sampled patients had a weight on record near week 68. Missing a recorded weight does not itself prove someone stopped treatment. Neither study establishes Embody's dropout rate.

Why "93% kept it off" doesn't add up

Embody ties this number to data from patients' first six months of treatment. Weight can be kept off while treatment continues or after it stops. But six months of data cannot establish that weight stayed off for good; the claim needs a defined follow-up period and a clear account of who was counted.¹

We cover what studies show after people stop further down.

Where the other numbers seem to come from

The "6x" figure matches a famous trial. In STEP 1, people on brand-name semaglutide lost 14.9% on average. People on placebo (a shot with no drug) lost 2.4%. Both groups got diet and exercise coaching.

Divide 14.9 by 2.4 and you get about 6.2. That's our reading of a match, not proof of where Embody got its number.

We also found this set of numbers on MEDVi's site on September 24, 2026: 18%, 93%, 6x, and 15–20%. Its main results footnote attributes data to MEDVi patients over their first six months.¹⁵

Both sites identify OpenLoop Health as a clinical network. That doesn't tell us whether their datasets overlap or how the matching figures were calculated. It also does not, by itself, prove either claim false. Our MEDVi results check has the details.¹⁶¹⁵

What the customer stories show

The deal.joinem.co sale page shows 13 distinct customer quotes in its text, excluding repeated copies. Six give a number of pounds lost. One gives a time frame. None gives a starting weight, so you can't turn any of them into a percentage. This count is for that page—not every Embody landing page.¹

We don't reprint customer stories or before-and-after photos on our site. Our editorial standards explain why.

Not sure a compounded medicine is right for you at all? That's a fair place to be. The right GLP-1 path depends on your state, your insurance, your budget, FDA-approved or compounded, and shot or pill. Our free Find My GLP-1 Path tool asks 8 quick questions plus a state and age check, and takes about 2 minutes. You don't need to sign up or give an email to see your match. A licensed clinician still makes every treatment decision.¹⁷

Is 18% realistic? Embody's number next to real studies

Embody's 18% claim covers six months; the 14.9% semaglutide result in STEP 1 covers 68 weeks. Those are different clocks. A Mayo Clinic practice saw 10.9% at six months, but in a different patient group with its own treatment and follow-up. None of these studies tested Embody's compounded products.¹⁴⁵

Here's each number with its clock attached. Read the "who was counted" column before you compare.

Embody's 18% is about 1.7 times what the Mayo Clinic practice saw at six months. It's also higher than the semaglutide figures in this table. That does not prove Embody outperforms those treatments: the patients, products, and methods differ. The Mayo study also accepted patient-reported weights; self-reporting is not unique to Embody.⁴

This is not a complete table of every newer trial. The current Wegovy label reports 18.8% at 72 weeks for its 7.2 mg injection study arm. That is a different regimen and a much longer follow-up—not evidence for Embody's six-month claim. Study doses here identify the research; they are not instructions for your treatment.⁵

People with type 2 diabetes tend to lose less. In STEP 2, which enrolled adults with type 2 diabetes, semaglutide 2.4 mg averaged 9.6% at 68 weeks, as reported in the Wegovy label.

Here's what the percentages look like in pounds. Embody's first two columns are unverified claims, not study averages. This is arithmetic, rounded to the nearest pound—not a forecast for you or a comparison of equal treatments and time periods.

For more brand-name reference calculations—not an Embody forecast—see our GLP-1 weight loss calculator.

Why a compounded medicine can't borrow these results

The research rows in that table studied specified drug products or followed patients using brand-name medicines; the Embody row is only a company claim. Embody sells compounded semaglutide and tirzepatide. Its offer page describes pharmacy preparation for individual prescriptions, not FDA-approved products.⁸

FDA says it doesn't review compounded drugs for safety, effectiveness, or quality before they're sold. FDA also says compounded drugs should only be used when a patient's medical needs can't be met by an FDA-approved drug.

We found no published randomized trial of Embody's compounded products in the public sources searched. A study from another program does not establish results for Embody's prescriptions.

So treat the table as selected clinical context. It isn't a promise for a compounded product.

Shortage-based flexibility is not a blanket route today. FDA's posted policy says the semaglutide and tirzepatide shortages are resolved and limits on making drugs that are essentially copies of approved products apply. Under the patient-specific pathway, a clinician must document a significant difference for the individual patient where that exception is used. A lower price alone is not that documented medical difference.¹⁸

One more label check. FDA says some compounded semaglutide is made with salt forms, like semaglutide sodium or semaglutide acetate. FDA calls these different active ingredients than the ones in approved drugs. Ask the pharmacy to identify the form supplied. Do not treat a salt form as an interchangeable substitute or guess from a product name. Our guide to what pharmacy Embody uses shows how to find out who filled your order.

"Pounds of fat every week"? Not all of it is fat

Embody's homepage talks about losing fat every week. Weight-loss studies of the approved products measured losses in both fat and lean mass—not fat alone.¹⁶¹⁹

The Wegovy label says semaglutide causes more fat loss than lean-mass loss. That means some lean mass goes too. In a body-scan study inside the tirzepatide trial, about a quarter of the tissue people lost was lean mass, which includes muscle.

Ask your clinician about enough protein and appropriate strength training. See how to prevent muscle loss on a GLP-1.

If you'd rather consider an FDA-approved weight-management product with its own trial evidence, Wegovy and Zepbound are options to discuss with a clinician. Ask your own prescriber first: an existing prescription filled through NovoCare or a Lilly access route may avoid an extra telehealth membership. Your visit, medicine, and any pharmacy fees still have their own costs.

Need a telehealth prescribing and follow-up route? Ro offers both medicines, and says its cash prices match the drug makers' own programs. Ro's membership is $39 for the first month, then as low as $74 a month with an annual plan paid upfront ($888), or $149 month to month. Medicine is billed separately.¹²

Embody weight loss results by month: what to expect

We found no independently verified month-by-month results for Embody patients. The Wegovy injection label uses gradual dose increases before its 2.4 mg maintenance dose (the ongoing dose) can start at week 17. That is label information for that approved product—not an Embody schedule or a reason to wait with troubling symptoms. Ask your clinician when to review your own progress.⁵

Before you judge your progress, write down three dates. The day you paid. The day you took your first dose. And the day your clinician plans to review how it's going.

These can be weeks apart. Say you paid three weeks ago, but your medicine arrived last week. That's one week on treatment, not three.

Embody's product pages say the dose ramps up "as clinically appropriate." Its separate offer FAQ does publish a suggested schedule, but one row has unclear dose units and the page gives inconsistent timing descriptions. Do not use it to work out your prescription. Its outcome footnote also refers to patients without diabetes who reached and maintained 2.4 mg weekly; it does not show how each headline maps to that subgroup. Ask your clinician about your written plan and review date—not when to reach an advertised dose.⁷⁸¹⁶

Is "1 to 2 pounds a week" realistic?

Embody's fine print says patients "typically" lose 1 to 2 pounds a week after week 4. By week 26, that adds up to 22 to 44 pounds. For a 200-pound person, that's 11% to 22%. That is multiplication of an advertised pace, not an observed six-month result.¹⁶

Here's the check. In STEP 4, people who stayed on brand-name semaglutide for 20 weeks lost 10.6% on average. For a 200-pound person, that's about 21 pounds, or about 1 pound a week when averaged across 20 weeks.²⁰

Dividing a trial's total loss by its length gives an arithmetic average, not proof of a steady weekly pace. It does not validate Embody's 1-to-2-pound weekly promise for its own patients.

Embody's separate offer FAQ also claims an average loss of 1.5% of body weight each week, then describes up to 10% over 12 weeks. It does not explain how those numbers fit together. For a 200-pound example, 1.5% of the starting weight repeated for 26 weeks is 78 pounds; 1.5% of the remaining weight each week is about 65 pounds. Those are different calculations, neither a supported Embody forecast. Don't build your goal around that wording.⁸

Can you lose 20 pounds in 2 months on Embody?

Twenty pounds in about nine weeks is a little over 2 pounds a week. For a 200-pound person, that's 10% in two months.

In the Mayo Clinic study, people on brand-name semaglutide averaged 5.9% after three months. That is a different treatment group and a longer period. We could not establish 20 pounds in two months as a typical Embody result.⁴

If fast weight loss comes with vomiting, dizziness, or trouble keeping fluids down, call your clinician.⁵

Semaglutide or tirzepatide: which gets bigger results?

In SURMOUNT-5, a head-to-head trial in 751 adults without diabetes, tirzepatide averaged 20.2% weight loss at 72 weeks. Semaglutide averaged 13.7%. The trial used the maximum tolerated studied injection regimens, not Embody's compounded versions, the Wegovy pill, or the newer 7.2 mg Wegovy injection.²¹

At Embody, compounded tirzepatide lists at $129 for a one-month supply, and compounded semaglutide at $79.⁷ See semaglutide vs. tirzepatide and our Embody tirzepatide review.

Does Embody refund you if it doesn't work?

Not for disappointing weight loss under the policy we checked. Embody's refund policy, updated August 25, 2026, says "There is no guarantee of results." Payments are generally final. A provider-initiated finding that you no longer medically qualify has a limited refund exception, after charges for services already provided—not an automatic full refund.²

We lined up the current public results-and-refund statements we could verify:

What this means for you:

• Plan as if there's no refund for slow results. That is what the checked policy says. We could not verify a current written results-refund offer elsewhere; get any different promise in writing before paying.
• A longer plan puts more money at risk. The policy says multi-month bundles are not refundable in whole or in part, apart from its stated medical exception. A shorter commitment limits how much you prepay; it doesn't establish how long is clinically appropriate to assess treatment.
• Canceling stops future charges only. The policy requires notice at least 72 hours before your next billing date. Don't rely on a shipment-cancellation line elsewhere on the site: billing and shipping dates can differ. Canceling does not itself refund past charges. See how to cancel Embody.²¹⁶
• Get any promise in writing. If someone at Embody offers a refund for results, ask for it by email and save a screenshot.

What does it cost to find out if Embody works for you?

At unchanged Embody product-page prices, six one-month supplies would total $474 for compounded semaglutide and $774 for compounded tirzepatide. The Wegovy pen illustration totals $2,578 for six fills and six Ro membership payments. These are examples using current listed rates—not verified renewal quotes, a prescribed dose path, or six calendar months of treatment. The lower price buys access, not proven Embody results.⁷¹²¹³

Table note: Six medication fills and, for Ro, six monthly membership payments are the units used in this illustration. Six 28-day fills cover 168 days (24 weeks), not six calendar months. Extra visits, a different billing cycle, fees, or taxes can change the bill; we did not complete checkout. An unknown cost is not assumed to be zero.

A few things change these totals:

• Embody shows other prices too. Its deal and exclusive offer pages list $69 and $119, and its Terms list older price schedules. Before you pay, confirm the product, plan, amount due today, renewal amount and date, and whether a longer plan is prepaid. We did not verify which offer your checkout applies.¹⁸⁹
• A "one-month" supply may last four weeks. Six months can take a seventh fill.
• The $199 Wegovy starter price has a deadline. NovoCare's current terms make it available for two qualifying 0.25 mg or 0.5 mg fills through December 31, 2026—not simply for anyone who signs up before then and fills later. The illustration assumes both fills qualify and later listed rates remain unchanged.¹³
• The medicine lines are price examples, not a schedule to follow. Your clinician sets your treatment. Zepbound's $449 higher-dose offer requires qualifying purchases; after the first, the next refill must be purchased within 45 days of delivery or receipt to keep that offer. Other dose choices or missed offer conditions change the total, and additional fees or taxes may apply.²²
• Embody says its price doesn't rise with your dose. Its FAQ ties that statement to staying on the same medicine and plan. Confirm your actual renewal terms rather than treating it as an independent price guarantee.¹⁶

Have insurance that might cover Wegovy or Zepbound? Check that before paying cash for anything. A covered prescription may cost less, but check the copay, deductible, eligibility, and any program fees before assuming that.¹²

Say you're 220 pounds, paying cash, and curious but unsure. Six supplies at an unchanged $79 price would total $474. That arithmetic tells you the spending at those rates—not whether you're eligible, whether six supplies are the right review period, or whether the treatment is equivalent to brand-name medicine. Ask your clinician when to assess progress before committing to a longer plan.

Your Embody results check: before you pay and before each renewal

The best way to judge Embody is on your own numbers, with your clinician. This check keeps your treatment and your bills in one place, so an ad never becomes your deadline.

Here's a billing message you can copy. It keeps health details out of billing, where they don't belong.

Please confirm my plan name, the amount I've paid, the date my paid time ends,
my next charge amount and date, and the exact deadline and time zone for a
cancellation request to prevent renewal. Please tell me which terms apply to my order and
send written confirmation. This is a billing question only.

Send it to Embody support at support@joinem.co. Send health questions to your clinician through the patient portal instead. These are copyable messages, not a form; we don't collect your answers here.²

Before you choose Embody, run four quick checks:

1. Is your BMI 30 or higher, or 27 or higher with a weight-related condition like high blood pressure? BMI means body mass index, a measure based on height and weight. Those are common adult medication-screening thresholds—not an Embody approval or a medical reason for compounding. A clinician must check both. Not sure of your BMI? Use our BMI calculator; an unknown answer is not a “yes.”²³³
2. Are you OK with a compounded medicine that isn't FDA-approved?
3. Can you live with no refund if it doesn't work for you?
4. Are you paying cash, not using insurance or Medicare?

Ready to review the plan with those limits in mind? Embody's product-page prices are lower than the brand-name examples above, but price alone doesn't establish the right treatment. One heads-up: its sale pages repeat results claims that we could not independently verify. Decide with your clinician and the actual price and terms—not those numbers.⁷¹⁸

Review Embody's plans and intake steps Have commercial insurance you want to check instead? Ro's free checker looks at Ozempic, Wegovy, and Zepbound autoinjector pens and emails you a report. It does not check the Wegovy pill, Foundayo, or Zepbound KwikPen, and checking is not approval or a prescription. Check your coverage with Ro.²⁴

What do Embody's reviews say about results?

On September 24, 2026, Embody had a 3.8 out of 5 on Trustpilot from 8,474 reviews. In the 20 most-recent reviews visible in the list we checked, none gave a number of pounds lost. This is a small service snapshot, not a study of all Embody patients.¹⁴

Reviews can fall in more than one row. The star mix in this group was 13 five-star, 4 four-star, and 3 one-star. These counts describe only the 20 reviews on screen, not how common each issue is among patients.

Two more facts help you read the score. The profile says Embody invites reviews and has a paid Trustpilot plan; it also flags merged profiles. In our sample, all 11 reviews labeled invited were four or five stars. Of 8 labeled unprompted, 5 were five-star and 3 were one-star; the remaining review was labeled verified and was five-star. A platform rating is not a verified clinical outcome.¹⁴

Reviews can help you investigate service, but they do not establish typical weight loss. For billing and complaint patterns, see our full Embody review.

Already taking Embody and not losing weight?

A slow start isn't proof it's failing, and a marketing timeline cannot tell you why it is happening. Check your dates, written prescription, label, symptoms, and missed doses, then send your clinician the details. Dose increases in approved-product labels are not an instruction to wait, restart, or change an Embody prescription yourself.³⁵⁶

Work through this list before you change anything:

1. Count from your first dose, not the day you paid.
2. Write down your current dose in mg and how many weeks you've been on it.
3. Ask the pharmacy to walk through your label: mg measures the amount of drug; mg per mL is the concentration; syringe units mark a volume. Those numbers are not supposed to be numerically equal. The pharmacist should explain how your specific prescription and supplied syringe fit together; don't do a conversion on your own. Call before using it if anything is unclear. FDA has received reports of dosing mistakes with compounded semaglutide, some needing hospital care. See common injection mistakes.
4. Switched from another provider? Show your clinician both labels and your last-use date. Embody says transfer patients may continue a current dose when the clinician finds that appropriate, but that is not a promise for your prescription. Different medicines, concentrations, or syringes cannot be matched by copying a number.¹⁶³
5. Check how your medicine arrived and how old the vial is. FDA says not to use an injectable GLP-1 that arrives warm or with insufficient refrigeration; contact the pharmacy. For compounded GLP-1 multi-dose vials, it also says to discard within 28 days after first use, even if medicine remains or the compounder's instructions allow longer. Follow any earlier discard date, and use a new sterile needle and syringe for each dose. That vial rule is not a storage rule for every brand-name pen. See GLP-1 storage and temperature guidance.³
6. Count missed or late doses. Shipping delays count. The Wegovy label allows a clinician to consider restarting its dose-escalation process after two or more missed doses, but that label is not a restart plan for a compounded prescription. Ask your own clinician what to do next.⁵
7. Don't raise your own dose. That's your clinician's call.

Here's a message you can send your clinician. Fill in the brackets.

I'd like to review my progress, not change my dose on my own.
My label says [medicine, dose in mg, and pharmacy].
I took my first dose on [date].
My dated weight record is [details, if known and appropriate to my care].
I've noticed [side effects or other changes].
I've missed [number and dates / unsure] doses or had these refill gaps: [details].
How do you read my progress, and when should we review again?

Send it through your Embody patient portal. You can also reach Embody support at support@joinem.co or (347) 269-4270, or through its contact page.

Get medical help right away if you have: stomach pain that is severe or won't go away (it may spread to your back); vomiting or diarrhea and you can't keep fluids down; fainting; or very low blood sugar if you also take insulin or a sulfonylurea (a type of diabetes medicine). For trouble breathing or swelling of your face or throat, call 911. Don't wait for a portal reply. These symptom warnings come from the Wegovy label; they do not establish an identical safety profile for a compounded product.

For non-urgent questions about mild symptoms, see our GLP-1 SOS guide and when to message your provider. These are not emergency services.

Thinking of leaving? Know two things first. SnagRx's contact page names the same operator as Embody: Modern Metabolic Medicine, Inc. Shared ownership alone doesn't settle whether it fits; ask whether its billing, support, or pharmacy arrangements would actually resolve your reason for leaving. And if your goal is an FDA-approved product, discuss options with your own clinician; Ro offers FDA-approved Wegovy and Zepbound as an additional telehealth route. Read how to switch providers without a gap before you cancel anything.¹⁶¹²

What happens to your results if you stop?

In the withdrawal trials below, the groups who stopped the study medicine regained weight on average. A 2026 real-world study found smaller average regain, but many patients restarted or used other treatments, so it is not a forecast for stopping without further care. Plan for the long run, including the cost, with your clinician.²⁰²⁵²⁶

The STEP 4 and SURMOUNT-4 post-switch percentages use weight at the switch—not the original starting weight. These studies cannot tell you your own weight after stopping, and none tested Embody's compounded products.

Embody's FAQ says your price stays the same while you're on the same medicine and plan. Its homepage says you can pause or adjust your plan. Ask what price and terms apply if you cancel and come back later; a pause claim is not a refund promise.¹⁶²

Stopping Embody isn't the same as stopping treatment. Talk with your clinician about a plan for what comes next. See what happens when you stop a GLP-1 and GLP-1 maintenance programs.

Should you try Embody? Find your row

Embody is a route to consider when a clinician identifies an appropriate need for compounded medicine, you can pay cash, and you accept its actual billing terms. Wanting the lowest price is not enough. Find the next step that answers your situation—not someone else's.³²

How we checked Embody's results

We read Embody's public pages and policies, counted the claims and review sample described above, and compared them with primary studies, FDA guidance, and current drug labels. We did not buy Embody, take its medicine, test a product, complete paid checkout, or see any patient records.

What we actually verified

Embody weight-loss results table 12

What we checked	Where	Date checked
Results claims and fine print; counts, not endorsement, of customer stories	Embody's homepage, product listings, and the two public sale pages linked in Sources	September 24, 2026
Refund and results terms	Embody's refund policy (updated August 25, 2026) and Terms (updated April 24, 2026)	September 24, 2026
Rating, review count, and our 20-review tally	Trustpilot's visible most-recent list, excluding review highlights and company replies	September 24, 2026
Advertised prices and savings conditions—not completed checkout	Embody product and offer pages; Ro pricing; NovoCare and Lilly offer terms	September 24, 2026
FDA status and safety advice	FDA compounding and GLP-1 pages; current Wegovy and Zepbound prescribing information	September 24, 2026
Study findings and who was counted	Full primary papers for Mayo, both Cleveland cohorts, STEP 4, SURMOUNT-4, STEP 1 extension, the online cohort, and the body-scan study; current labels for STEP 1, STEP 2, and SURMOUNT-1; the authors' university-deposited abstract for SURMOUNT-5	September 24, 2026

Provider-stated vs. verified: We verified that Embody publishes these claims. We did not verify that they are true.

What we couldn't confirm: the sample size, collection dates, and missing-data method behind Embody's claims; an individual patient's prescription or assigned pharmacy; the final checkout and renewal charge each reader would see; or a current written results-refund offer outside the checked policy. A public dosing FAQ exists, but its unclear units are not usable treatment instructions.

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

This article doesn't rank providers. When we do, we follow our published ranking method.

Embody weight loss results: FAQ

How soon will I see results with Embody?

We could not verify an Embody-specific timetable. With brand-name semaglutide, one Mayo Clinic practice saw 5.9% average loss among 175 patients at three months and 10.9% among 102 with six-month data. Those are study averages, not your personal deadline.⁴

How long should I stay on a GLP-1?

Your clinician decides that with you. Withdrawal-study groups regained weight on average after stopping the study drug; those averages do not say what every person will regain. Plan for follow-up and the ongoing cost, rather than choosing a stop date from an ad.²⁰²⁵²⁷

Does Embody actually work for weight loss?

The studied approved products produced weight loss in trials, but those results do not establish effectiveness for Embody's compounded prescriptions. We found no published randomized trial of Embody's products in the public sources searched. Embody's own refund policy says results aren't guaranteed.⁵⁶²

Is Embody's 18% average weight loss real?

It's Embody's claim, based on patients' self-reported weights in their first six months. The pages we checked did not give a sample size or collection dates. It is higher than STEP 1's 14.9% at 68 weeks, but different patients, products, and follow-up periods prevent a valid performance comparison.¹⁵

How much weight can I lose in my first month on Embody?

We could not verify a first-month average for Embody from the checked sources. Approved injection labels start with introductory doses, but that does not tell you your expected pounds or establish an Embody schedule. Ask your prescriber when to assess progress.⁵⁶

Will Embody refund me if I don't lose weight?

Not for slow or disappointing results under the policy we checked. Its provider-initiated medical-disqualification exception refunds unused value after deducting services already provided. It is not a satisfaction guarantee or an automatic full refund.²

Is Embody tirzepatide better than semaglutide?

In SURMOUNT-5's studied injection regimens, tirzepatide averaged 20.2% loss at 72 weeks, compared with 13.7% for semaglutide. Embody's compounded versions weren't tested. Its product pages list one-month supplies at $129 for compounded tirzepatide and $79 for compounded semaglutide; different offer pages show other prices.²¹⁷

Why am I not losing weight on Embody?

This page cannot diagnose the reason. Send your clinician your start date, written prescription, symptoms, missed doses, and any refill or storage concerns. An unclear label or warm delivery needs a pharmacy response, not a bigger dose or an assumed explanation for the scale.³

Are Embody before-and-after photos real?

Embody's fine print says testimonial images may use models and some content may be made with AI. That does not prove any particular picture is fabricated, but we couldn't independently verify the stories' weights or dates. We don't publish patient testimonials or before-and-after photos.¹⁶

Is Embody's compounded semaglutide the same as Wegovy?

No. Wegovy is FDA-approved. Compounded semaglutide isn't FDA-approved, isn't a generic, and FDA doesn't review it for safety, effectiveness, or quality before it's sold.³

What happens if I stop Embody?

Withdrawal-trial groups regained weight on average after stopping the study medicine. A 2026 Cleveland Clinic study found smaller average regain in routine care, where restarting and other treatments occurred; it does not predict what happens without further treatment. Ask your clinician about a plan before you stop.²⁰²⁵²⁶

Can I use insurance or Medicare with Embody?

Embody's Terms say its clinicians aren't contracted with insurance plans, including Medicare and Medicaid; don't assume it will bill your plan. It advertises HSA/FSA use—health savings or flexible spending account funds—but we did not test card acceptance, and advertising does not determine tax eligibility. See does Embody take insurance and does Embody accept HSA/FSA.⁹¹⁶

Still not sure which GLP-1 path fits you? Take our free Find My GLP-1 Path quiz — about 2 minutes, no signup.

Sources

Public pages checked September 24, 2026. Policy and publication dates below identify the source, not a different page-level verification date. Study doses describe research, not treatment instructions.

Additional original reports: STEP 1; SURMOUNT-1; online-program cohort, published online in December 2025 and in a 2026 journal issue. The STEP 1, STEP 2, and SURMOUNT-1 figures used above were also checked in the current approved-product labels.